Kymera Therapeutics, Inc.

Overview

Kymera Therapeutics, Inc. is a U.S.-based clinical-stage biopharmaceutical company developing oral medicines through targeted protein degradation, an approach that uses cells’ natural recycling processes to remove disease-causing proteins. Its research focuses on immunology and inflammatory diseases. The company describes its mission as discovering and developing medicines that improve the lives of patients with serious diseases.[1][2]

Kymera’s pipeline includes drug candidates targeting STAT6, IRF5 and IRAK4, including programs for immunological and inflammatory conditions; it also has a collaboration with Gilead to develop CDK2 degraders.[3]+3

The company is headquartered in Watertown, Massachusetts, and its clinical-development activities include international studies. At year-end 2025, it had 238 full-time employees and reported $39.2 million in collaboration revenue for the year.[7]+2 [1]+9

Products & services

Kymera Therapeutics’ product portfolio consists of investigational targeted protein degraders; the company reported no product candidates approved for sale. KT-621 is an oral, once-daily STAT6 degrader in Phase 2b trials for moderate-to-severe atopic dermatitis in adults and adolescents and asthma in adults. STAT6 mediates IL-4/IL-13 signaling associated with Type 2 inflammation.[10][4]

KT-579 is an oral IRF5 degrader in Phase 1 testing in healthy volunteers, with lupus identified as a potential indication for a planned subsequent proof-of-concept study.[11][12] KT-485 (SAR447971) is an oral IRAK4 degrader in a Sanofi-led Phase 1 study in healthy adults and people with hidradenitis suppurativa; Sanofi leads its development, regulatory, and commercial activities.[5][13] KT-200 is an oral CDK2 molecular-glue degrader licensed to Gilead and in IND-enabling studies, with potential application in breast cancer and other solid tumors.[14][15]

Kymera also disclosed other early-stage programs without naming specific products; KT-474 was discontinued after Sanofi selected KT-485 for development.[13][16] No product-sale revenue or product contribution as a percentage of company performance was reported; disclosed revenue included collaboration and milestone payments instead.[17]+2 [10]+11

Geographic presence

Kymera Therapeutics is headquartered at 500 North Beacon Street, 4th Floor, Watertown, Massachusetts. Its principal headquarters site includes approximately 100,624 square feet of office and laboratory space; the company also reported 34,522 square feet of additional Watertown office and laboratory space that it did not then occupy and intended to sublease.[20][7]

The company reports conducting, or potentially conducting, clinical trials outside the United States, including in Europe, Asia, and other geographies, and says it works with vendors located in Asia and Europe. Its filings do not provide revenue by country or region, or an employee count or workforce distribution by geography.[21]+2 [20]+4

Business segments

Kymera Therapeutics reports one operating and reportable segment, focused on developing medicines to address significant health problems. The company does not report separate therapeutic-area segments or segment-level contribution percentages; its business is therefore represented by this single segment.[24]

The segment’s assets are reported as total consolidated assets, so it accounts for 100% of reported segment assets. The filing does not provide separate segment revenue or other contribution figures.[25] [24][25]

Company history

Kymera Therapeutics traces its inception to 2015 and was founded in May 2016 by Nello Mainolfi and others at Atlas Venture; Mainolfi and Bruce Booth were identified as co-founders.[26]+2 The company raised Series A and B financing in 2017 and 2018, and established research collaborations with GSK in 2017 and Vertex in 2019.[29]+3

In 2020, Kymera entered a collaboration with Sanofi on IRAK4 and another target, and completed its initial public offering.[33][34] The company began clinical testing of its IRAK4 degrader KT-474 in 2021, followed by oncology programs KT-333 and KT-413 in 2022.[35][36] KT-474 advanced into Phase 2 in 2023, while Kymera discontinued KT-413; in 2024, its STAT6 degrader KT-621 entered clinical testing.[37]+2

In 2025, Kymera reported Phase 1 results for KT-621 and initiated Phase 2b studies, while entering a CDK2 degrader collaboration with Gilead.[40]+2 In 2026, Gilead exercised its option to license KT-200, and Kymera advanced KT-579 into Phase 1; in July, Terence Rooney became Chief Medical Officer, succeeding Jared Gollob.[14]+2 [26]+19

Sources

• Kymera Therapeutics, Inc. — Full financial report (2025 Y)
  14 citations

  [1][2][3][7][8][9][20][22][23][26][33][37][40][41]
• Kymera Therapeutics, Inc. — Press release (2026 Q 2)
  6 citations

  [4][5][10][11][12][15]
• www.kymeratx.com[6]
• Kymera Therapeutics, Inc. — Full financial report (2026 Q 2)
  10 citations

  [13][14][16][17][18][19][21][24][25][42]
• www.kymeratx.com[27]
• investors.kymeratx.com[28]
• Kymera Therapeutics, Inc. — Full financial report (2020 Y)
  3 citations

  [29][30][34]
• www.prnewswire.com[31]
• www.prnewswire.com[32]
• www.nasdaq.com[35]
• www.prnewswire.com[36]
• investors.kymeratx.com[38]
• kymeratx.gcs-web.com[39]
• www.sec.gov[43]
• www.sec.gov[44]